Epigenetics Therapeutics to 2017: High Market Potential for Epigenetics Drugs

01 Oct 2010 • by Natalie Aster
Epigenetics Therapeutics to 2017: High Market Potential for Epigenetics Drugs

“Epigenetic drugs are the chemical compounds or biologics that cause epigenetic changes resulting in modified molecular protein expressions, these drugs have the potential to trigger or suppress a protein expression process. Epigenetic drugs are currently approved to treat MDS and CTCL, which are cancers of the blood cells.”

Currently, there are four epigenetic drugs in the market; Vidaza, Zolinza, Dacogen and Istodax. The sales of these drugs amounted to $517m in 2009. Vidaza and Dacogen are approved for the indication Myelodysplastic Syndrome (MDS) and Zolinza and Istodax are approved for the indication Cutaneous T-cell lymphoma (CTCL). Of all the drugs, Vidaza had the largest market share in 2009, followed by Dacogen.

The report "Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma" by GBI Research provides in-depth analysis of trends, issues and challenges in this industry.

Report Details

Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma
Published: August 2010
Price: US$ 3,500.00 US$ 3,150.00 Order the report now and receive a 10% discount!
Discount period - Upto 30th Oct’10

Report Highlights

  • Vidaza by Celgene is one of the therapies commonly employed to treat MDS. Vidaza’s uptake in the top seven markets will be driven by epidemiological factors and an escalation in Vidaza price.
  • The annual cost of therapy ranges from $45,135 to $49,886. It is estimated to reach revenues of $604m by the year 2017.
  • Vidaza is in the late stage of clinical trials for the treatment of Acute Myeloid Leukemia (AML). As Vidaza is approved for MDS, which is a precursor to AML, it is expected to be widely accepted after being approved for AML.
  • Vidaza is estimated to achieve peak sales of $312m for AML by the year 2012 in the top seven markets.

To order the report or ask for free sample pages contact ps@marketpublishers.com


Contacts

MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com